- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05337566
Formindsker yderligere brug af præoperativ azithromycin posthysterektomiinfektioner
Infektioner efter hysterektomi - en placebokontrolleret undersøgelse, der sammenligner den profylaktiske brug af azithromycin og cefuroxim med enkelt cefuroxim
During hysterectomy bacteria may enter into the peritoneal cavity through vaginal opening and contaminate the healing tissues. The risk for deep infection after hysterectomy is about 5%. By reducing post-hysterectomy infections, it is possible to reduce individual burden of disease in addition to the direct and indirect financial costs. This study primary aim is to assess if prophylactic preoperative use of azithromycin in addition to generally used cefuroxime decreases post-hysterectomy infections as compared to cefuroxime only prophylaxis during 30 days after hysterectomy. Secondary aim is to assess if there is change in post-hysterectomy superficial infections, urinary tract infections, or post-operative fever between the cohorts and to report possible side-effects of the used antibiotics. In addition, the study finds out a possible role of bacterial vaginosis and microbiome n post-hysterectomy infections.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Päivi K Rahkola-Soisalo, Adj prof,MD
- Telefonnummer: +358504270411
- E-mail: paivi.rahkola-soisalo@hus.fi
Undersøgelse Kontakt Backup
- Navn: Ninja Savonius, MD
- Telefonnummer: +358503466986
- E-mail: ninja.savonius@hus.fi
Studiesteder
-
-
-
Helsinki, Finland
- Rekruttering
- Helsinki University Central Hospital
-
Kontakt:
- Ninja Savonius, MD
- Telefonnummer: +358503466986
- E-mail: ninja.savonius@hus.fi
-
Kontakt:
- Päivi K Rahkola-Soisalo, Adj prof,MD
- Telefonnummer: +358 50 4270411
- E-mail: paivi.rahkola-soisalo@hus.fi
-
Underforsker:
- Liisu Saavalainen, PhD, MD
-
Underforsker:
- Päivi Härkki, Adj prof, MD
-
Underforsker:
- Tomi Mikkola, Prof, MD
-
Underforsker:
- Veli-Jukka Anttila, Adj prof,MD
-
Underforsker:
- Seppo Virtanen, DI, MD
-
Underforsker:
- Anne Saloranta, Adj Prof
-
Underforsker:
- Ilkka Kalliala, Adj Prof, MD
-
Underforsker:
- Suvi Niku, PhD, MD
-
Jyväskylä, Finland, 40620
- Rekruttering
- Jyväskylä Central Hospital
-
Kontakt:
- Jaana Seikkula, PhD
- Telefonnummer: +358 41 548 3562
- E-mail: jaana.seikkula@fimnet.fi
-
Kuopio, Finland, 70029
- Rekruttering
- Kuopio University Central Hospital
-
Kontakt:
- Henna Kärkkäinen, PhD
- Telefonnummer: +358 44 7172741
- E-mail: henna.karkkainen@kuh.fi
-
Oulu, Finland, PL23
- Rekruttering
- Oulu University Central Hospital
-
Kontakt:
- Sari Koivurova, PhD
- Telefonnummer: +358 8 3150211
- E-mail: sari.koivurova@ppshp.fi
-
Tampere, Finland, 33521
- Rekruttering
- Tampere University Central Hospital
-
Kontakt:
- Riikka Niemi, PhD
- Telefonnummer: +358 3 31169083
- E-mail: riikka.niemi@pshp.fi
-
Underforsker:
- Elina Ylilehto, PhD, MD
-
Turku, Finland
- Rekruttering
- Turku University Central Hospital
-
Kontakt:
- Pia Heinonen, PhD
- Telefonnummer: +358 2 313 5002
- E-mail: pia.heinonen@tyks.fi
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Women undergoing hysterectomy for benign indication in University Hospitals (Helsinki University Hospital, Turku University Hospital, Tampere University Hospital, Oulu University Hospital and Kuopio University Hospital) who have not any contraindications for azithromycin or cefuroxime.
Exclusion Criteria:
- Inability to understand the study protocol.
- Allergy for either cefuroxime or azithromycin.
- Congenital or acquired prolonged Q-T-corrected interval. All the participants will be asked about arrhythmias and whether they have congenital arrhythmias in the family,
- Electrocardiogram will be checked for all the participants.
- Use of medicines that may prolong Q-T-corrected interval (class Ia arrhythmia medications, quinidine, procainamide, and class III arrhythmia medications dofetilide, amiodarone and sotalol).
- Use of selective serotonin reuptake inhibitor medication and prolonged Q-T-corrected interval.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Azithromycin + Cefuroxime
Changed with renewed study permissions: These patients will receive Azithromycin 500 mg (2 tablets) per orally on the operation day when they arrive to the hospital and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more) in the operating theatre before the incision. The previous description: These patients will receive Azithromycin 500 mg (2 tablets) per orally in the evening before the operation and single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision. |
Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision |
|
Aktiv komparator: Placebo + Cefuroxime
Changed with new study permissions: These patients will receive placebo (2 tablets) per orally on the operation day when they arrive to the hospital and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more)in the operating theatre before the incision. The previous description: These patients will receive placebo (2 tablets) per orally in the evening before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision. |
Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of post-hysterectomy episodes with deep infections
Tidsramme: Deep infections that occur between the first and 30th postoperative day after hysterectomy
|
Number of deep wound and pelvic organ infection episodes reported by patients and doctors |
Deep infections that occur between the first and 30th postoperative day after hysterectomy
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of other post-hysterectomy infections or fever episodes
Tidsramme: Number of other infections or fever episodes that occur between the first and 30th postoperative day after hysterectomy.
|
Number of superficial infections, other infections, such has urine tract infections, or fever episodes lasting over 38 ℃ over 2 days |
Number of other infections or fever episodes that occur between the first and 30th postoperative day after hysterectomy.
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Päivi Rahkola-Soisalo, Adj prof, MD, Helsinki University Central Hospital
- Studiestol: Tomi Mikkola, Prof, MD, Helsinki University Central Hospital
- Studieleder: Päivi Rahkola-Soisalo, Adj prof, MD, Helsinki University Central Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HUS/117/2022
- 2021-003467-10 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .